These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 39092218)
1. PD-1 inhibitors in advanced esophageal squamous cell carcinoma: a survival analysis of reconstructed patient-level data. Yan C; Cao W; Li J; Zhang L; Diao R Front Pharmacol; 2024; 15():1408458. PubMed ID: 39092218 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety evaluation of frontline immunotherapy combinations in advanced esophageal squamous cell carcinoma: a network meta-analysis highlighting the value of PD-L1 expression positivity scores. Chen W; Cao K; Zhang L; Zhao X; Chen B; Li W; Shang R; Sun L; Jiang Z; Wang J; Xue W Front Immunol; 2024; 15():1414753. PubMed ID: 39050848 [TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors Liu S; Dou L; Li S Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis. Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202 [TBL] [Abstract][Full Text] [Related]
5. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer. Shao T; Zhao M; Liang L; Tang W Front Immunol; 2022; 13():948597. PubMed ID: 36389713 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of First-line Therapies for Advanced Unresectable Oesophageal Squamous Cell Cancer: a Systematic Review and Network Meta-analysis. Nian Z; Zhao Q; He Y; Xie R; Liu W; Chen T; Huang S; Dong L; Huang R; Yang L Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):30-38. PubMed ID: 37827946 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis. Li Y; Liang X; Li H; Chen X Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898 [TBL] [Abstract][Full Text] [Related]
8. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials. Lu Y; Wang W; Wang F Front Immunol; 2023; 14():1171671. PubMed ID: 37205107 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis. Gao TT; Shan JH; Yang YX; Zhang ZW; Liu SL; Xi M; Liu MZ; Zhao L BMC Cancer; 2022 Sep; 22(1):992. PubMed ID: 36115960 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis. Li J; Chen Y; Hu F; Qiang H; Chang Q; Qian J; Shen Y; Cai Y; Chu T Front Oncol; 2022; 12():1001503. PubMed ID: 36523992 [TBL] [Abstract][Full Text] [Related]
11. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer. Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347 [TBL] [Abstract][Full Text] [Related]
12. Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis. Zhao M; Shao T; Ren Y; Zhou C; Tang W Front Pharmacol; 2022; 13():910656. PubMed ID: 36249794 [No Abstract] [Full Text] [Related]
13. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis. Yang X; Zheng X; Hu S; Huang J; Zhang M; Huang P; Wang J BMC Cancer; 2024 May; 24(1):654. PubMed ID: 38811891 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Squamous Cell Cancer of the Esophagus. Thuss-Patience P; Stein A Curr Oncol; 2022 Mar; 29(4):2461-2471. PubMed ID: 35448174 [TBL] [Abstract][Full Text] [Related]
15. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative. Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661 [TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: A network meta-analysis. Lin S; Liu T; Chen J; Li G; Dang J PLoS One; 2021; 16(6):e0252751. PubMed ID: 34086780 [TBL] [Abstract][Full Text] [Related]
17. Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis. Huang S; Huang Z; Huang X; Luo R; Liang W; Qin T Front Immunol; 2024; 15():1375136. PubMed ID: 39072325 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis. Liu S; Zhao L; Shi F; Kuai L; Liu R; Tang J Int J Clin Pharm; 2024 Jun; 46(3):675-683. PubMed ID: 38407692 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis. Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis. Liu BW; Shang QX; Yang YS; Chen LQ Front Oncol; 2023; 13():1077675. PubMed ID: 37114136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]